The U.S. Food and Drug Administration (FDA) revised the boxed warning on the label for adalimumab (Yuflyma) on 2026-07-08. The updated warning emphasizes the increased risk of serious infections, which can lead to hospitalization, and the potential for malignancy. This revision highlights critical safety information for prescribers and patients.

Details of the Revised Warning

The updated boxed warning for adalimumab (Yuflyma) reiterates critical safety information regarding serious infections and malignancy. Specifically, it highlights an increased risk of serious infections that may lead to hospitalization. The warning also advises healthcare professionals to refer to the full prescribing information for complete details on these risks, including specific sections 5.1 and 6.1, which address serious infections and malignancy, respectively. The full prescribing information should be consulted for comprehensive details on these safety concerns.

What this means

The revised boxed warning for adalimumab (Yuflyma) serves as a critical update for all healthcare providers, including clinicians, pharmacists, and nurses, involved in the care of patients receiving this medication. The emphasis on serious infections and malignancy necessitates a thorough review of patient medical history, including any prior or current infections, and a careful assessment of malignancy risk factors before initiating or continuing treatment. Providers should counsel patients extensively on the signs and symptoms of serious infections and the importance of prompt reporting. Regular monitoring for adverse events, particularly those related to infection and malignancy, remains paramount. This update reinforces the need for vigilance in balancing the therapeutic benefits of adalimumab with its known safety profile, ensuring optimal patient outcomes and adherence to the latest FDA guidance. The warning applies to all products marketed under the adalimumab (Yuflyma) label.

Source

This label revision was reported by the FDA on 2026-07-08. The full prescribing information is available on dailymed.nlm.nih.gov.